Amodiaquine

DB00613ApprovedInvestigationalSmall molecule

Amodiaquine is an antimalarial drug. A 4-aminoquinoquinoline compound with anti-inflammatory properties.

Mechanism: The mechanism of plasmodicidal action of amodiaquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites. The drug binds the free heme preventing the parasite from converting it to a form less toxic. This drug-heme complex is toxic and disrupts membrane function.
Curator reviewed
Primary indication: For treatment of acute malarial attacks in non-immune subjects.Curator reviewed
Formula / weight: C₂₀H₂₂ClN₃O · 355.861 g/mol (avg)
Code names: NSC-13453 · S. N. 10751

Resolves to

Compound

UNII220236ED28CAS86-42-0ChEMBLCHEMBL682ChEBI2674PubChem3647519KEGGD02922

Clinical / RWD

RxNorm720ATCP01BA06ATCP01BF03PharmGKBPA448404

Structure

InChIKeyOVCDSSHSILBFBN-UHFFFAOYSA-NSMILESCCN(CC)CC1=C(O)C=CC(NC2=C3C=CC(Cl)=CC3=NC=C2)=C1

Targets

P50135HNMT

Transporters

P08183ABCB1

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1TransporterSubstrate / inhibitor direction, not just membership

Listed above

767Drug interactionsStructured to mechanism, not free text

72Clinical trialsPhase, status and sponsor resolved per trial

2Marketed productsAcross 2 countries and 2 labellers

2ATC codesIncluding every combination product, plus 19 drug categories

26+ReferencesStructured and connected to the statements they support

Which drugs share a target with Amodiaquine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In